Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865)

J. A. Green, E. M J J Berns, C. Coens, I. van Luijk, J. Thompson-Hehir, P. van Diest, R. H M Verheijen, M. van de Vijver, P. van Dam, G. G. Kenter, W. Tjalma, P. C. Ewing, I. Teodorovic, I. Vergote, M. E L van der Burg

Research output: Contribution to journalArticle

Abstract

Purpose: The study was designed to determine independent prognostic variables in suboptimally debulked advanced ovarian cancer patients entered in the randomised phase III study EORTC 55865. Experimental design: Retrospectively collected paraffin blocks from 169 patients with stages IIb-IV epithelial ovarian cancer, taken at primary debulking surgery, were analysed. All patients were treated with cyclophosphamide and cisplatin (CP), and followed up for a median of 10 years. Expression of p53, bcl-2, P21, Ki-67 and HER-2 status was assessed by immunohistochemistry (IHC). Results: Expression of p21, a downstream effector of the p53 gene, was found to be a favourable prognostic factor for survival (HR 0.58, CI 0.36-0.94, p = 0.025) in addition to FIGO stage (HR 1.54, CI 1.08-2.21, p = <0.02). For progression free survival (PFS), both p21 (HR 0.52) and Ki-67 (HR 0.6) were significant factors. Conclusion: P21 overexpression is a positive prognostic factor for survival and PFS in advanced ovarian carcinoma with residual lesions of more than 1 cm.

Original languageEnglish (US)
Pages (from-to)2539-2548
Number of pages10
JournalEuropean Journal of Cancer
Volume42
Issue number15
DOIs
StatePublished - Oct 2006
Externally publishedYes

Keywords

  • Bcl-2
  • DNA ploidy
  • Immunohistochemistry
  • MIB-1
  • Morphometry
  • P21
  • P53
  • Prognosis
  • Suboptimally debulked advanced ovarian cancer

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865)'. Together they form a unique fingerprint.

  • Cite this

    Green, J. A., Berns, E. M. J. J., Coens, C., van Luijk, I., Thompson-Hehir, J., van Diest, P., Verheijen, R. H. M., van de Vijver, M., van Dam, P., Kenter, G. G., Tjalma, W., Ewing, P. C., Teodorovic, I., Vergote, I., & van der Burg, M. E. L. (2006). Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865). European Journal of Cancer, 42(15), 2539-2548. https://doi.org/10.1016/j.ejca.2006.06.015